Vimarsana
Biggest News Aggregation in the World

Page 2 - Servier Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Servier Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Servier Group Today - Breaking & Trending Today

Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress - Vimarsana News

Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced updated data from the...

Protecting wildcats, a new tool against cancer, and galaxies far, far away - Vimarsana News

Protecting wildcats, a new tool against cancer, and galaxies far, far away

Saving Spots is an initiative that protects leopards in Zambia while ensuring the cultural traditions of the Lozi people stay intact.

Experiment Drug Touted as Breakthrough for Intractable Brain Cancer - Vimarsana News

Experiment Drug Touted as Breakthrough for Intractable Brain Cancer

A new experimental drug therapy has shown some promising signs of slowing down the progression of a type ...

Drug developer Servier's brain cancer drug slows tumor progession considerably - Vimarsana News

Drug developer Servier's brain cancer drug slows tumor progession considerably

Study involving 331 patients showed vorasidenib significantly improved progression-free survival

Experimental drug shown to 'significantly' slow progression of brain cancer - Vimarsana News

Experimental drug shown to 'significantly' slow progression of brain cancer

A new experimental drug was found to "significantly" reduce the progression of brain cancer, Reuters reported. Vorasidenib, created by Servier Group, a…

Source: biztoc.com